CRVL
VENTE TOTALE: 6 847 titres (~481 488,31 $ US)
- Insiders
- JESSUP R JUDD
- Total bought
- —
- Total sold
- $481,488
- Last activity
- 2026-09-01
- Last synced
-
2026-09-07 10:23:47
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-05
CRVL exhibits genuinely strong fundamentals — high ROE/ROIC, solid liquidity, and improving margins — but the event-driven signal is decisively bearish, with a catalyst score of only 20 driven by meaningful insider…
The first sentence of the analysis written for CRVL on 2026-09-05 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 24.3% | 23.4% | 21.6% | 22.0% | 23.5% | |
| Ebit Margin | 14.9% | 13.5% | 12.0% | 11.8% | 13.1% | |
| Ebitda Margin | 18.2% | 16.8% | 15.3% | 15.3% | 16.8% | |
| Operating Profit Margin | 14.9% | 13.5% | 12.0% | 11.8% | 13.1% | |
| Pretax Profit Margin | 14.9% | 13.5% | 12.0% | 11.8% | 13.1% | |
| Continuous Operations Profit Margin | 11.5% | 10.6% | 9.6% | 9.2% | 10.3% | |
| Net Profit Margin | 11.5% | 10.6% | 9.6% | 9.2% | 10.3% | |
| Bottom Line Profit Margin | 11.5% | 10.6% | 9.6% | 9.2% | 10.3% | |
| Current Ratio | 2.027 | 1.895 | 1.638 | 1.452 | 1.546 | |
| Quick Ratio | 2.027 | 1.895 | 1.638 | 1.452 | 1.546 | |
| Solvency Ratio | 0.571 | 0.557 | 0.495 | 0.477 | 0.445 | |
| Cash Ratio | 1.022 | 0.836 | 0.572 | 0.425 | 0.569 | |
| Price To Earnings Ratio | 25.419 | 60.524 | 57.824 | 49.555 | 44.920 | |
| Price To Earnings Growth Ratio | 1.567 | 2.421 | 3.701 | 20.648 | -0.898 | |
| Forward Price To Earnings Growth Ratio | 1.567 | 2.421 | 3.701 | 20.648 | -0.898 | |
| Price To Earnings Diluted Ratio | 25.537 | 61.186 | 58.218 | 50.341 | 46.025 | |
| Price To Earnings Diluted Growth Ratio | 1.508 | 2.498 | 3.493 | 15.354 | -0.899 | |
| Price To Book Ratio | 7.109 | 17.870 | 17.751 | 16.309 | 14.080 | |
| Price To Sales Ratio | 2.924 | 6.425 | 5.527 | 4.589 | 4.628 | |
| Price To Free Cash Flow Ratio | 25.413 | 62.843 | 62.801 | 58.915 | 79.953 | |
| Price To Operating Cash Flow Ratio | 18.007 | 45.194 | 44.297 | 40.071 | 44.487 | |
| Debt To Assets Ratio | 0.044 | 0.051 | 0.069 | 0.086 | 0.104 | |
| Debt To Equity Ratio | 0.071 | 0.087 | 0.127 | 0.167 | 0.203 | |
| Debt To Capital Ratio | 0.067 | 0.080 | 0.113 | 0.143 | 0.169 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.631 | 1.696 | 1.836 | 1.948 | 1.955 | |
| Working Capital Turnover Ratio | 4.599 | 5.963 | 8.215 | 8.478 | 6.459 | |
| Operating Cash Flow Ratio | 0.682 | 0.624 | 0.538 | 0.490 | 0.392 | |
| Operating Cash Flow Sales Ratio | 0.162 | 0.142 | 0.125 | 0.115 | 0.104 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.709 | 0.719 | 0.705 | 0.680 | 0.556 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 5.537 | 4.534 | 3.161 | 2.437 | 1.558 | |
| Capital Expenditure Coverage Ratio | 3.431 | 3.561 | 3.394 | 3.126 | 2.254 | |
| Dividend Paid And Capex Coverage Ratio | 3.431 | 3.561 | 3.394 | 3.126 | 2.254 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 14.853 | 37.320 | 35.613 | 29.722 | 27.079 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 24.3% | ▲0.9% | ▲1.3% |
| Ebit Margin | 14.9% | ▲1.4% | ▲1.9% |
| Ebitda Margin | 18.2% | ▲1.5% | ▲1.8% |
| Operating Profit Margin | 14.9% | ▲1.4% | ▲1.9% |
| Pretax Profit Margin | 14.9% | ▲1.4% | ▲1.9% |
| Continuous Operations Profit Margin | 11.5% | ▲0.9% | ▲1.3% |
| Net Profit Margin | 11.5% | ▲0.9% | ▲1.3% |
| Bottom Line Profit Margin | 11.5% | ▲0.9% | ▲1.3% |
| Current Ratio | 2.027 | ▲0.132 | ▲0.315 |
| Quick Ratio | 2.027 | ▲0.132 | ▲0.315 |
| Solvency Ratio | 0.571 | ▲0.015 | ▲0.062 |
| Cash Ratio | 1.022 | ▲0.186 | ▲0.337 |
| Price To Earnings Ratio | 25.419 | ▼-35.106 | ▼-22.230 |
| Price To Earnings Growth Ratio | 1.567 | ▼-0.854 | ▼-3.920 |
| Forward Price To Earnings Growth Ratio | 1.567 | ▼-0.854 | ▼-3.920 |
| Price To Earnings Diluted Ratio | 25.537 | ▼-35.648 | ▼-22.724 |
| Price To Earnings Diluted Growth Ratio | 1.508 | ▼-0.991 | ▼-2.883 |
| Price To Book Ratio | 7.109 | ▼-10.761 | ▼-7.515 |
| Price To Sales Ratio | 2.924 | ▼-3.501 | ▼-1.895 |
| Price To Free Cash Flow Ratio | 25.413 | ▼-37.430 | ▼-32.572 |
| Price To Operating Cash Flow Ratio | 18.007 | ▼-27.187 | ▼-20.404 |
| Debt To Assets Ratio | 0.044 | ▼-0.008 | ▼-0.027 |
| Debt To Equity Ratio | 0.071 | ▼-0.016 | ▼-0.060 |
| Debt To Capital Ratio | 0.067 | ▼-0.014 | ▼-0.048 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.631 | ▼-0.065 | ▼-0.182 |
| Working Capital Turnover Ratio | 4.599 | ▼-1.364 | ▼-2.144 |
| Operating Cash Flow Ratio | 0.682 | ▲0.058 | ▲0.137 |
| Operating Cash Flow Sales Ratio | 0.162 | ▲0.020 | ▲0.033 |
| Free Cash Flow Operating Cash Flow Ratio | 0.709 | ▼-0.011 | ▲0.035 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 5.537 | ▲1.003 | ▲2.092 |
| Capital Expenditure Coverage Ratio | 3.431 | ▼-0.129 | ▲0.278 |
| Dividend Paid And Capex Coverage Ratio | 3.431 | ▼-0.129 | ▲0.278 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 14.853 | ▼-22.467 | ▼-14.065 |
Key metrics
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Market cap | $2.80B | $5.75B | $4.40B | $3.30B | $2.99B | |
| Enterprise value | $2.60B | $5.61B | $4.32B | $3.26B | $2.94B | |
| EV / Sales | 2.71x | 6.27x | 5.43x | 4.54x | 4.54x | |
| EV / Op. cash flow | 16.69x | 44.08x | 43.55x | 39.61x | 43.68x | |
| EV / Free cash flow | 23.55x | 61.29x | 61.74x | 58.24x | 78.50x | |
| EV / EBITDA | 14.85x | 37.32x | 35.61x | 29.72x | 27.08x | |
| Net debt / EBITDA | -1.17x | -0.95x | -0.61x | -0.34x | -0.50x | |
| Current ratio | 2.03x | 1.90x | 1.64x | 1.45x | 1.55x | |
| Income quality | 1.41x | 1.34x | 1.30x | 1.24x | 1.01x | |
| Graham number | $19 | $16 | $13 | $11 | $11 | |
| Graham net-net | $1 | $0 | -$1 | -$1 | -$1 | |
| Tax burden | 77.1% | 78.8% | 80.2% | 78.5% | 78.6% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $234.2M | $182.7M | $117.7M | $75.9M | $93.6M | |
| Invested capital | $410.4M | $332.8M | $265.3M | $224.4M | $243.4M | |
| Return on assets | 17.2% | 17.4% | 16.8% | 16.8% | 16.0% | |
| Operating ROA | 24.1% | 24.1% | 22.4% | 20.9% | 20.1% | |
| Return on tangible assets | 18.2% | 18.7% | 18.3% | 18.6% | 17.6% | |
| Return on equity | 28.0% | 29.6% | 30.8% | 32.8% | 31.3% | |
| Return on invested capital | 26.1% | 27.2% | 27.3% | 28.1% | 25.8% | |
| Return on capital employed | 34.5% | 35.3% | 35.2% | 37.4% | 34.7% | |
| Earnings yield | 3.9% | 1.7% | 1.7% | 2.0% | 2.2% | |
| Free cash flow yield | 3.9% | 1.6% | 1.6% | 1.7% | 1.3% | |
| Capex / Op. cash flow | 29.1% | 28.1% | 29.5% | 32.0% | 44.4% | |
| Capex / Depreciation | 142.8% | 121.1% | 111.4% | 104.8% | 124.7% | |
| Capex / Sales | 4.7% | 4.0% | 3.7% | 3.7% | 4.6% | |
| SG&A / Sales | 9361.4% | 9.9% | 9.6% | 10.3% | 10.5% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.6% | 0.6% | 0.6% | 0.8% | 0.8% | |
| Intangibles / Total assets | 5.8% | 6.8% | 8.3% | 9.7% | 9.3% | |
| Days sales outstanding | 39d | 42d | 45d | 41d | 47d | |
| Days payables outstanding | 12d | 8d | 10d | 10d | 10d | |
| Operating cycle | 39d | 42d | 45d | 41d | 47d | |
| Cash conversion cycle | 26d | 34d | 35d | 31d | 36d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-51.3%EV / Sales ▼-56.7%EV / EBITDA ▼-60.2%EV / Op. cash flow ▼-27.385Earnings yield ▲+0.023Graham number ▲+3.134
Profitability
Return on equity ▼-0.016Return on assets ▼-0.003Return on invested capital ▼-0.011Return on capital employed ▼-0.008Operating ROA ▼-0.001Income quality ▲+0.073Tax burden ▼-0.017
Efficiency
Days sales outstanding ▼-3.858Days payables outstanding ▲+4.027Operating cycle ▼-3.858Cash conversion cycle ▼-7.885Capex / Sales ▲+0.007R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.132Net debt / EBITDA ▼-0.224Working capital ▲+51576000.000Invested capital ▲+77594000.000Intangibles / Total assets ▼-0.011
Change over 5 years
Valuation
Market cap ▼-6.3%EV / Sales ▼-40.4%EV / EBITDA ▼-45.2%EV / Op. cash flow ▼-26.988Earnings yield ▲+0.017Graham number ▲+8.714
Profitability
Return on equity ▼-0.033Return on assets ▲+0.012Return on invested capital ▲+0.003Return on capital employed ▼-0.002Operating ROA ▲+0.040Income quality ▲+0.398Tax burden ▼-0.015
Efficiency
Days sales outstanding ▼-8.067Days payables outstanding ▲+1.833Operating cycle ▼-8.067Cash conversion cycle ▼-9.900Capex / Sales ▲+0.001R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.481Net debt / EBITDA ▼-0.671Working capital ▲+140605000.000Invested capital ▲+166981000.000Intangibles / Total assets ▼-0.035
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-03 Head to Head Analysis: CorVel (NASDAQ:CRVL) versus Wellgistics Health (NASDAQ:MEDS) Wellgistics Health (NASDAQ: MEDS - Get Free Report) and CorVel (NASDAQ: CRVL - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability. Earnings and Valuation This table compares Wellgistics Health and
- 2026-08-12 Assenagon Asset Management S.A. Sells 95,906 Shares of CorVel Corp. $CRVL Assenagon Asset Management S.A. reduced its stake in CorVel Corp. (NASDAQ: CRVL) by 48.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 101,952 shares of the business services provider''s stock after selling 95,906 shares during the period.
- 2026-08-05 CorVel Corporation (CRVL) Q1 2027 Earnings Call Prepared Remarks Transcript CorVel Corporation (CRVL) Q1 2027 Earnings Call Prepared Remarks Transcript
- 2026-08-05 CorVel Q1 Earnings Call Highlights CorVel NASDAQ: CRVL reported June-quarter revenue of $260 million, up 11% from $235 million in the June 2025 quarter, while earnings per share rose 22% to $0.63 from $0.52 a year earlier.
- 2026-08-05 CorVel Announces Revenues and Earnings FORT WORTH, Texas, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) announced the results for the quarter ended June 30, 2026. Revenues for the quarter were $260 million, an increase from $235 million in the June quarter of 2025. Earnings per share for the quarter were $0.63, compared to $0.52 in the same quarter of the prior year.
- 2026-07-27 CorVel Corporation to Host Live Earnings Release Webcast FORT WORTH, Texas, July 27, 2026 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL), a leading provider of innovative risk management solutions, is pleased to announce that it will host a live webcast to discuss its upcoming quarterly earnings results on Wednesday, August 5, 2026, at 11:30 AM Eastern Time.
- 2026-07-08 CorVel Named 2026 PropertyCasualty360 Insurance Luminaries Winner for Excellence in Claims Management CorVel earned the 2026 PropertyCasualty360 Insurance Luminaries Award for Excellence in Claims Management for its integrated, technology-enabled approach.
- 2026-06-17 CorVel Launches Marketwise Repricing™ to Deliver Smarter, Market-Based Medical Cost Containment FORT WORTH, Texas, June 17, 2026 (GLOBE NEWSWIRE) -- CorVel Corporation (Nasdaq: CRVL), a national provider of risk management solutions, today announced the launch of CorVel Marketwise Repricing™, a market-based medical bill repricing solution designed to enhance cost containment while fitting seamlessly into existing bill review programs. As medical billing continues to vary widely across states, providers, and care settings, traditional network and re-pricing approaches do not always reflect market pricing.